The 2009 ISI Impact Factors (IFs) have just been released, and Expert Opinion has had a good year:
Expert Opinion on Investigational Drugs = 4.218
Expert Opinion on Therapeutic Targets = 3.713
Expert Opinion on Biological Therapy = 3.215
Expert Opinion on Drug Metabolism and Toxicology = 3.076
Expert Opinion on Drug Safety = 2.496
Expert Opinion on Emerging Drugs = 2.407
Expert Opinion on Pharmacotherapy = 2.018
Expert Opinion on Therapeutic Patents = 1.280
Expert Opinion on Drug Delivery has now received its first IF, emerging with a strong first showing of 3.345.
The IF indicates a publication’s influence within the global research community. In a given year, the IF of a journal reflects the average number of citations to those papers that were published during the two preceding years. Expert Opinion’s 2009 IFs therefore account for the number of articles published from 2007-2008, which were cited in 2009.
Further information on IF’s can be found on the ISI Web of Knowledge website, under Journal Citation Reports.
Showing posts with label impact factor. Show all posts
Showing posts with label impact factor. Show all posts
Monday, 28 June 2010
Tuesday, 22 June 2010
Rising Impact Factors, Strong Growth, Solidifies Journals as Leading Resources
Informa Healthcare – one of the world’s leading medical and scientific publishers – has released its latest Journal Impact Factor* results, with outstanding performances across the division’s diverse selection of peer-reviewed journals.
Highlights included Critical Reviews in Biochemistry and Molecular Biology, which registered a staggering 10.216 Impact Factor, up 23% from 8.306 last year; The World Journal of Biological Psychiatry, increased more than 55% to 5.564; and Chronobiology International jumped up to 3.987.
Impact Factors are a method of measuring the influence which a journal has on the scientific community. They are calculated by Thomson Reuters and are designed to indicate how many times the published articles of a journal are cited during the course of a year, providing an insight to how much ‘impact’ the journal is making on the scientific community.
“The Impact Factor can help validate the importance of our journals to the medical and scientific communities we serve,” explains Phil Garner, Divisional Managing Director at Informa Healthcare.
“We are extremely proud of the high quality information which we publish for our readers and the wide range of healthcare fields covered by our titles. We are delighted that this year’s Impact Factor increases for each journal clearly reflect the quality and importance of the research and pinpoint how much it is being used throughout the year”
Informa’s Expert Opinion series – which provides in-depth analysis of the pharmaceutical R&D pipeline – has registered noteworthy performances in Expert Opinion on Investigational Drugs which increased its Impact Factor to 4.218, and Expert Opinion on Drug Delivery which impressed with a first-ever Impact Factor of 3.345.
“These results demonstrate the comprehensive, intelligent content that makes our Expert Opinion journals the definitive reference source for leading pharmaceutical scientists,” says Phil.
Four other Informa titles to enter the market with a remarkable impact include: Journal of Immunotoxicology with a first-ever impact factor of 1.218; Computer Aided Surgery with an impact factor of 1.221; Logopedics, Phoniatrics Vocology had a 1.175 Impact Factor in its first year; and Australasian Psychiatry entering the market at 0.657.
“We are justifiably proud of the performance of all of our journals,” adds Phil. “Our established journals have continued to move from strength to strength, with many titles solidifying an upward trend in their respective rankings.”
The World Journal of Biological Psychiatry moved up 22 places in the Psychiatry category, while the Amyotrophic Lateral Sclerosis Impact Factor increased 63% to 2.963, moving 37 places up within its Clinical Neurology sector. The Scandinavian Journal of Primary Health Care also moved up 13 places with a 27.9% Impact Factor increase to 2.205.
Other titles that registered impressive Impact Factor performances were: Cancer Investigation, with an increased impact factor of 2.105; Autoimmunity at 2.813; Critical Reviews in Microbiology with 3.207; Leukemia & Lymphoma at 2.397; and Nanotoxicology which registered a 72.5% increase to 5.774.
“Our overall performance – together with the outstanding individual performances of many of our titles – ensures that Informa continues to serve as a leading force in medical and scientific publishing, providing the market with the lion’s share of must-read titles,” explains Phil.
*© Thomson Reuters, Journal Citation Reports® 2010
Highlights included Critical Reviews in Biochemistry and Molecular Biology, which registered a staggering 10.216 Impact Factor, up 23% from 8.306 last year; The World Journal of Biological Psychiatry, increased more than 55% to 5.564; and Chronobiology International jumped up to 3.987.
Impact Factors are a method of measuring the influence which a journal has on the scientific community. They are calculated by Thomson Reuters and are designed to indicate how many times the published articles of a journal are cited during the course of a year, providing an insight to how much ‘impact’ the journal is making on the scientific community.
“The Impact Factor can help validate the importance of our journals to the medical and scientific communities we serve,” explains Phil Garner, Divisional Managing Director at Informa Healthcare.
“We are extremely proud of the high quality information which we publish for our readers and the wide range of healthcare fields covered by our titles. We are delighted that this year’s Impact Factor increases for each journal clearly reflect the quality and importance of the research and pinpoint how much it is being used throughout the year”
Informa’s Expert Opinion series – which provides in-depth analysis of the pharmaceutical R&D pipeline – has registered noteworthy performances in Expert Opinion on Investigational Drugs which increased its Impact Factor to 4.218, and Expert Opinion on Drug Delivery which impressed with a first-ever Impact Factor of 3.345.
“These results demonstrate the comprehensive, intelligent content that makes our Expert Opinion journals the definitive reference source for leading pharmaceutical scientists,” says Phil.
Four other Informa titles to enter the market with a remarkable impact include: Journal of Immunotoxicology with a first-ever impact factor of 1.218; Computer Aided Surgery with an impact factor of 1.221; Logopedics, Phoniatrics Vocology had a 1.175 Impact Factor in its first year; and Australasian Psychiatry entering the market at 0.657.
“We are justifiably proud of the performance of all of our journals,” adds Phil. “Our established journals have continued to move from strength to strength, with many titles solidifying an upward trend in their respective rankings.”
The World Journal of Biological Psychiatry moved up 22 places in the Psychiatry category, while the Amyotrophic Lateral Sclerosis Impact Factor increased 63% to 2.963, moving 37 places up within its Clinical Neurology sector. The Scandinavian Journal of Primary Health Care also moved up 13 places with a 27.9% Impact Factor increase to 2.205.
Other titles that registered impressive Impact Factor performances were: Cancer Investigation, with an increased impact factor of 2.105; Autoimmunity at 2.813; Critical Reviews in Microbiology with 3.207; Leukemia & Lymphoma at 2.397; and Nanotoxicology which registered a 72.5% increase to 5.774.
“Our overall performance – together with the outstanding individual performances of many of our titles – ensures that Informa continues to serve as a leading force in medical and scientific publishing, providing the market with the lion’s share of must-read titles,” explains Phil.
*© Thomson Reuters, Journal Citation Reports® 2010
Tuesday, 2 September 2008
Expert Opinion on Drug Discovery indexed by ISI
We are delighted to announce that Expert Opinion on Drug Discovery is now indexed on ISI web of Science.
Subscribe to:
Posts (Atom)
